Amgen Inc.AMGNNASDAQ

Overview Intelligence Charts News Fundamentals

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating

Hold

28 analysts·High coverage

50%

Rating Distribution

Strong Buy

00%

Buy

1450%

Hold

1139%

Sell

311%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Current price is 8% above analyst consensus — modest downside expected.

Bear Case

$185.00

-51%

Consensus

$347.00

-8%

Bull Case

$432.00

+15%

Price Range28 analysts

Low

Consensus

High

$185.00

$432.00

Current Target

Current Price

$377.00

Above Target

$30.00

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$22.40(20 analysts)

P/E26x

Current: 26.4x

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+2.76%

EPS+4.15%

FY2028

Rev+1.89%

EPS+3.19%

FY2029

Rev+4.61%

EPS+5.06%

Earnings Surprises

Beat rate:92%(11/12 quarters)

Avg surprise:+7.9%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Feb 19, 2026Barclays

Amgen initiated with an Equal Weight at Barclays

Target:$185.00

-50.7%from $375.50

Feb 19, 2026Wells Fargo

Amgen price target raised to $375 from $325 at Wells Fargo

Target:$375.00

-1.2%from $379.73

Feb 18, 2026Piper Sandler

Amgen price target raised to $432 from $381 at Piper Sandler

Target:$432.00

+15.7%from $373.36

Feb 11, 2026Mizuho Securities

Amgen price target raised to $295 from $280 at Mizuho

Target:$295.00

-19.1%from $364.65

Feb 4, 2026RBC Capital

Amgen price target raised to $360 from $335 at RBC Capital

Target:$360.00

+0.8%from $357.29

Feb 4, 2026Morgan Stanley

Amgen price target raised to $309 from $304 at Morgan Stanley

Target:$309.00

-12.2%from $351.81

Jan 29, 2026Oppenheimer

Amgen price target raised to $400 from $380 at Oppenheimer

Target:$400.00

+16.4%from $343.57

Jan 26, 2026UBS

Amgen price target raised to $390 from $380 at UBS

Target:$390.00

+11.8%from $348.99

Jan 20, 2026Bernstein

Amgen downgraded to Market Perform from Outperform at Bernstein

Target:$335.00

+1.4%from $330.44

Jan 6, 2026UBS

Amgen assumed at Buy from Neutral at UBS

Target:$380.00

+15.1%from $330.17

Dec 12, 2025Morgan Stanley

Amgen price target lowered to $304 from $329 at Morgan Stanley

Target:$304.00

-4.3%from $317.67

Dec 10, 2025HSBC

Amgen price target raised to $425 from $381 at HSBC

Target:$425.00

+35.4%from $313.85

Dec 3, 2025BMO Capital

Amgen price target raised to $372 from $335 at BMO Capital

Target:$372.00

+9.9%from $338.36

Nov 25, 2025Wells Fargo

Goldman Sachs Reiterates Buy Rating on Amgen (AMGN)

Target:$400.00

+19.7%from $334.30

Nov 24, 2025Truist Financial

Amgen assumed with a Hold at Truist

Target:$318.00

-5.4%from $336.19

Nov 14, 2025Piper Sandler

Amgen (AMGN) PT Raised to $381 at Piper Sandler

Target:$381.00

+14.6%from $332.43

Nov 6, 2025Cantor Fitzgerald

Amgen price target raised to $315 from $305 at Cantor Fitzgerald

Target:$315.00

-1.1%from $318.40

Nov 5, 2025Wells Fargo

Amgen price target raised to $300 from $280 at Wells Fargo

Target:$300.00

+1.1%from $296.70

Aug 25, 2025Piper Sandler

Amgen price target raised to $342 from $328 at Piper Sandler

Target:$342.00

+18.6%from $288.47

May 2, 2025UBS

Amgen price target lowered to $315 from $319 at UBS

Target:$315.00

+12.0%from $281.22

Apr 22, 2025Cantor Fitzgerald

Amgen assumed at Neutral from Overweight at Cantor Fitzgerald

Target:$305.00

+9.6%from $278.40

Mar 5, 2025Johnson Rice

Amgen price target raised to $294 from $275 at BofA

Target:$294.00

-7.1%from $316.57

Nov 12, 2024Jefferies

Jefferies on Amgen (AMGN): 'Thoughts on Phase I bone data for AMG-133 - seems non-issue'

Target:$380.00

+27.2%from $298.84

Nov 12, 2024Cantor Fitzgerald

Cantor Fitzgerald Locates Data on Amgen (AMGN) Hidden in Tables for MariTide's Data

Target:$405.00

+35.5%from $298.84

Oct 21, 2024Morgan Stanley

Morgan Stanley names Amgen 'catalyst-driven idea' into Phase 2 MariTide data

Target:$319.00

+0.7%from $316.74

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance